See the DrugPatentWatch profile for cosentyx

The maximum usage time for Cosentyx (secukinumab) has not been definitively established as it depends on individual patient response and the specific condition being treated. However, according to the Cosentyx prescribing information, the drug has been studied in clinical trials for up to 5 years for psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

In terms of patent information, Cosentyx is a brand-name drug for secukinumab, which is a human monoclonal antibody that targets interleukin-17A (IL-17A) [2]. According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2025, which may lead to the availability of generic versions of the drug [3]. However, the maximum usage time for secukinumab is not directly related to its patent status.

It is important to note that the use of Cosentyx should be under the supervision of a healthcare provider, who will determine the appropriate duration of treatment based on the patient's individual needs and response to the medication.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Secukinumab. In: Lexi-Drugs Online [database online]. Hudson, OH: Lexi-Comp, Inc.; 2021. Available from: <https://online.lexi.com/>.
3. Secukinumab (cosentyx) Drug Patent Expiration. DrugPatentWatch.com. Available from: <https://www.drugpatentwatch.com/secukinumab-cosentyx>.